Pre-earnings options volume in Trevi Therapeutics (TRVI) is normal with calls leading puts 1:1. Implied volatility suggests the market is anticipating a move near 6.8%, or 0c, after results are released. Median move over the past eight quarters is 3.0%.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRVI:
- TRVI Earnings this Week: How Will it Perform?
- Trevi Therapeutics Aligns With FDA on Phase 3 Cough Trials
- De-Risked Phase 3 Strategy and FDA Alignment Underpin Buy Rating on Trevi for Haduvio in IPF Cough
- Trevi completes EOP2 with FDA, on track for Q2 Phase 3 initiation, says Stifel
- Advancing Haduvio in IPF-Related Chronic Cough: FDA-Endorsed Phase 3 Path and Strong Cash Position Underscore Undervalued Multibillion-Dollar Opportunity for Trevi